Sign in
Taking people in United StatesPhase 2

Guanfacine for Alcohol Use Disorder (AUD)

Key facts

Who runs it
Indiana University
Where
Indianapolis and Newark, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
3 Oct 2025
Expected to end
7 Sept 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Guanfacine Extended Release (XR)
  • Placebo
Record updated
11 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • be assigned as a biological male or female at birth and identify as such
  • meet current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) criteria for moderate to severe AUD
  • be ≥18 years old and have a body mass index (BMI) of 18-35
  • express a desire to quit alcohol as determined by the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)
  • demonstrate a positive urine for alcohol on admission to study procedures
  • be able to provide informed verbal and written consent
  • be able to read English and complete study evaluations
  • be in good health as verified by the intake 1 physical examination

Who cannot take part

  • regular use of medications in the last 6 months that, in the opinion of the site physician may be contraindicated with GXR and be potentially harmful to the participant
  • meet criteria for moderate to severe Substance Use Disorder (SUD), excluding alcohol and nicotine
  • have cardiovascular disease including high blood pressure,
  • have bradycardia with a sitting heart rate (HR) of <60 bpm
  • show EKG evidence of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) >470 msec for women and QTc>450 msec for men
  • have a positive screen for substances of abuse, excluding alcohol, nicotine,
  • being psychotic or otherwise severely psychiatrically disabled (including suicidal, homicidal, current mania)
  • meet criteria for physiological dependence on alcohol requiring medical detoxification
  • be pregnant or breast feeding
  • be using monophasic contraceptives
  • be hypotensive with sitting blood pressure below 100/50 mmHG

This trial is currently available in United States.

  • The Stark Neuroscience Building (Goodman Hall)Indianapolis, United StatesContact: Helen C Fox, PhDTaking people
  • Rutgers School of Health ProfessionalsNewark, United StatesContact: Suchismita Ray, PhDTaking people

About the trial

What the trial wants to find out

The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.

The 2 groups in the trial

  • Guanfacine Extended Release (XR)Treatment being tested

    Participants receive guanfacine XR, 3mg tablet orally, once per day for 12 weeks

  • PlaceboPlacebo, for comparison

    Participants receive guanfacine XR, placebo tablet orally, once per day for 12 weeks

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
Record updated
11 May 2026